Explore baxter.com

This global site is intended for Healthcare Professionals only. All products may not be available in all countries. Contact your local Baxter representative

Renal Care

Therapies

We deliver and support renal therapies across the continuum of care, including the innovative HDx.

Therapies
  • Acute Therapy

    Organ support and blood purification therapies are essential to improving patient outcomes in the ICU.

  • Peritoneal Dialysis

    Peritoneal Dialysis - combined with Remote Patient Management - offers the potential to improve renal patients' clinical outcomes and increase lifestyle flexibility.

  • Hemodialysis

    Hemodialysis is the predominant therapy for end-stage kidney disease, and can be delivered through multiple therapy options.

  • HDx Therapy

    HDx - also known as expanded hemodialysis - is an innovative therapy that effectively targets the removal of large middle molecules.

Products

Learn more about Baxter’s key products for Renal Care – across the continuum of care.

Data & Insights

Groundbreaking research and inspirational patient stories.

  • Clinical Data

    Explore the research enabling innovative Renal Care.

  • Stories

    Patients’ journeys inspire our work and drive our commitment.

  • Resource Library

    Access resources for Baxter’s broader Renal Care portfolio.

Explore baxter.com

This global site is intended for Healthcare Professionals only. All products may not be available in all countries. Contact your local Baxter representative

Medium Cut-Off Dialysis Membrane and Dietary Fiber Effects on Inflammation and Protein-Bound Uremic Toxins: A Systematic Review and Protocol for an Interventional Study.

Learn More
  • "Three studies examined the reduction in inflammatory markers with MCO membranes compared to high-flux HD membranes and showed no significant differences.
    Planned study to compare 4 weeks of HDx with 4 weeks of on-line HDF in 50 patients on high-flux HD at enrollment. The 2 main outcomes of the study will be serum concentrations of p-cresol sulfate and IL-6.
    Secondary outcomes will include serum concentrations of indoxyl-sulfate, trimethylamine-N-oxide, IL-10, serum amyloid A, hs-CRP, and total leukocyte count
    (see ClinicalTrials.gov NCT04247867)"